Skip to main content

Cryo-Cell International, Inc.

corporate_fare Company Profile

Cryo-Cell International, Inc.

CCEL·NYSE·Industrial Applications And Services·CIK 0000862692

Cryo-Cell International, Inc. is a Delaware corporation incorporated in 1989 that operates in three reportable segments: cellular processing and cryogenic storage for family use, with a current focus on the collection and preservation of umbilical cord blood and tissue stem cells; the manufacture of PrepaCyte® CB Processing System ("PrepaCyte CB") units, the processing technology used to process umbilical cord blood stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. In combination with its global affiliates, the Company currently stores over 250,000 cord blood and cord tissue specimens worldwide for the exclusive benefit of newborn babies and possibly other members of their families. Founded in 1989, Cryo-Cell was the world's first private cord blood bank to separate and store stem cells in 1992. Its U.S.-based business operations, including the processing and storage of specimens, are handled from its headquarters facility in Oldsmar, Florida. The specimens are primarily stored in commercially available cryogenic storage units at the Company's technologically and operationally advanced facility in Durham, NC. In recent years, utilizing its infrastructure, experience and resources derived from its umbilical cord blood stem cell business, the Company has expanded its research and development activities to develop technologies related to stem cells harvested from sources beyond umbilical cord blood stem cells. During fiscal 2011, Cryo-Cell introduced the advanced new cord tissue service, which stores a section of the umbilical cord tissue, offered in combination with the umbilical cord blood service. On February 23, 2021, the Company entered into a Patent and Technology License Agreement (the "Duke License Agreement") with Duke University, which grants the Company certain rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke.

Cryo-Cell International, Inc. (NYSE:CCEL) is a publicly traded company in the Industrial Applications And Services sector.

Financial Snapshot

Fiscal year ended November 30, 2025
Revenue
$31.57M
Net Income
-$2.43M
Diluted EPS
-$0.30
Op. Cash Flow
$5.48M
Free Cash Flow
$5.25M
Gross Profit
$24.19M
Operating Income
$482.39K
Cash & Equivalents
$319.03K
Total Debt
$8.35M
Debt / Equity
-0.45×
Net Margin
-7.7%
Shares Outstanding
8.06M sh
Source: 10-K · filed 2026-02-27 · accession 0001193125-26-083096

Short Interest & Short Volume

1.40 days to cover

FINRA reported short interest of 12,075 shares in CCEL as of the October 30, 2026 settlement, a 70.8% increase from the prior period — about 1.4 days to cover at its recent average daily volume. On November 19, 2026, 36.0% of CCEL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,075 shares as of October 30, 2026
Change vs prior period▲ 70.8%
Days to cover1.40 at avg daily volume of 8,654
Daily short volume (FINRA facilities)36.0% of 5,695 shares on November 19, 2026
5-day average short volume28.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$4.2 +1.08% today
Market cap
$33.82M
Volume
1.9K (0.2× avg)
3-mo avg 11.4K
Live data · 2026-11-20 20:47 UTC · Market open

show_chartPrice Chart

Loading chart...

feed CCEL - Latest Insights

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets